KYTX

Kyverna Therapeutics, Inc.

A clinical-stage biotech company engineering patients' own immune cells to fight autoimmune diseases such as lupus. Kyverna's lead therapy, KYV-101, is a CAR T-cell treatment that reprograms a patient's T cells to seek out and quiet the rogue immune cells driving the disease. Founded in 2018 in the San Francisco Bay Area, the company takes its name from the Greek word for "govern" or "guide," reflecting its aim to steer the immune system back into balance.

CUSIP: 501976104HealthcareUS1 holder

Ownership Activity Financials Filings

KYTX

KYTX

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Other Events

Regulation FD Disclosure